CHILDHOOD OSTEOPOROSIS AND PRESENTATION OF TWO CASES WITH OSTEOGENESIS IMPERFECTA TYPE V

被引:2
|
作者
Bratanic, Nina [1 ]
Dzodan, Bojana [1 ]
Trebusak Podkrajsek, Katarina [2 ,4 ]
Bertok, Sara [1 ]
Ostanek, Barbara [3 ]
Marc, Janja [3 ]
Battelino, Tadej [1 ,4 ]
Avbelj Stefanija, Magdalena [1 ]
机构
[1] Univ Childrens Hosp, Dept Pediat Endocrinol Diabet & Metab Dis, Ljubljana 1000, Slovenia
[2] Univ Med Ctr Ljubljana, Univ Childrens Hosp, Unit Special Lab Diagnost, Ljubljana 1000, Slovenia
[3] Univ Ljubljana, Fac Farmacy, Ljubljana 1000, Slovenia
[4] Univ Ljubljana, Fac Med, Ljubljana 1000, Slovenia
来源
ZDRAVSTVENO VARSTVO | 2015年 / 54卷 / 02期
关键词
bone mineral density; hypertrophic callus; IFITM5; gene; bisphosphonates; HYPERPLASTIC CALLUS FORMATION; BISPHOSPHONATE THERAPY; PHENOTYPIC VARIABILITY; FOLLOW-UP; MUTATION; CHILDREN; FRACTURES; POLYMORPHISM; ADOLESCENTS; PAMIDRONATE;
D O I
10.1515/sjph-2015-0018
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Introduction. Osteogenesis imperfecta (OI) is etiologically heterogeneous disorder characterized by childhood osteoporosis. A subtype OI type V is caused by the same c.-14C>T mutation in the IFITM5 gene. Nevertheless, there is a marked interindividual phenotypic variability in clinical presentation; however, response to bisphosphonates is reported to be good. Methods. Two individuals with OI type V had multiple recurrent fractures with hypertrophic calluses, scoliosis and ossifications of the forearm interosseous membranes. Sequencing of IFITM5, genotyping of variants rs2297480 in farnesyl diphosphate synthase gene (FDPS), and rs3840452 in geranylgeranyl diphosphate synthase 1 gene (GGPS1), both involved in bisphosphonate metabolism, was performed. Results. In patient 1 BMD reached normal values during bisphosphonate treatment and remained normal four years after the treatment discontinuation. In patient 2 no increase in BMD after five years of bisphosphonate treatment was observed and callus formation continued. The c.-14C>T IFITM5 mutation in heterozygous state was detected in both individuals. Additionally, both patients carried FDPS variant rs2297480 in homozygous state, and were heterozygous for GGPS 1 variant rs3840452. Conclusions. The paper presents a short overview of childhood osteoporosis with a special emphasis on OI type V by presenting two cases. Both OI type V patients had identical disease-causing mutation, but marked interindividual phenotypic variability. The striking failure in response to bisphosphonate treatment in one of the patients could not be explained by the variants in genes involved in bisphosphonate metabolism.
引用
收藏
页码:119 / 125
页数:7
相关论文
共 50 条
  • [21] Two years' experience with denosumab for children with Osteogenesis imperfecta type VI
    Hoyer-Kuhn, Heike
    Netzer, Christian
    Koerber, Friederike
    Schoenau, Eckhard
    Semler, Oliver
    ORPHANET JOURNAL OF RARE DISEASES, 2014, 9
  • [22] Crispr-Cas9 engineered osteogenesis imperfecta type V leads to severe skeletal deformities and perinatal lethality in mice
    Rauch, Frank
    Geng, Yeqing
    Lamplugh, Lisa
    Hekmatnejad, Bahareh
    Gaumond, Marie-Helene
    Penney, Janice
    Yamanaka, Yojiro
    Moffatt, Pierre
    BONE, 2018, 107 : 131 - 142
  • [23] Worsening of callus hyperplasia after bisphosphonate treatment in type V osteogenesis imperfecta
    Prajnya Ranganath
    Joshi Stephen
    Raju Iyengar
    Shubha R. Phadke
    Indian Pediatrics, 2016, 53 : 250 - 252
  • [24] The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta Type V
    Zeitlin, L
    Rauch, F
    Travers, R
    Munns, C
    Glorieux, FH
    BONE, 2006, 38 (01) : 13 - 20
  • [25] Worsening of callus hyperplasia after bisphosphonate treatment in type V osteogenesis imperfecta
    Ranganath, Prajnya
    Stephen, Joshi
    Iyengar, Raju
    Phadke, Shubha R.
    INDIAN PEDIATRICS, 2016, 53 (03) : 250 - 252
  • [26] Osteogenesis imperfecta type V: Genetic and clinical findings in eleven Chinese patients
    Liu, Yi
    Wang, Jiawei
    Ma, Doudou
    Lv, Fang
    Xu, Xiaojie
    Xia, Weibo
    Jiang, Yan
    Wang, Ou
    Xing, Xiaoping
    Zhou, Peiran
    Wang, Jianyi
    Yu, Wei
    Li, Mei
    CLINICA CHIMICA ACTA, 2016, 462 : 201 - 209
  • [27] Osteogenesis imperfecta. Report of 15 Cases
    Diaz Lopez, Maria
    Alegre Sancho, Juan Jose
    Martinez-Ferrer, Angels
    REUMATOLOGIA CLINICA, 2020, 16 (02): : 165 - 168
  • [28] Expanding the phenotypic spectrum of osteogenesis imperfecta type V including heterotopic ossification of muscle origins and attachments
    Clewemar, Pantelis
    Hailer, Nils P.
    Hailer, Yasmin
    Klar, Joakim
    Kindmark, Andreas
    Ljunggren, Osten
    Stattin, Eva-Lena
    MOLECULAR GENETICS & GENOMIC MEDICINE, 2019, 7 (07):
  • [29] Novel mutations in BMP1 induce a rare type of osteogenesis imperfecta
    Xu, Xiao-jie
    Lv, Fang
    Song, Yu-wen
    Li, Lu-jiao
    Asan
    Wei, Xiu-xiu
    Zhao, Xiu-li
    Jiang, Yan
    Wang, Ou
    Xing, Xiao-ping
    Xia, Wei-bo
    Li, Mei
    CLINICA CHIMICA ACTA, 2019, 489 : 21 - 28
  • [30] Sporadic osteogenesis imperfecta type V in an 11-year-old Japanese girl
    Fujino, Takashi
    Morii, Takeshi
    Tajima, Takashi
    Honya, Keita
    Horita, Ayako
    Mochizuki, Kazuo
    Satomi, Kazuhiko
    Fujioka, Yasunori
    JOURNAL OF ORTHOPAEDIC SCIENCE, 2010, 15 (04) : 589 - 593